L C Pagliaro

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:2965-70. 2002
  2. ncbi request reprint Gene therapy for bladder cancer
    L C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    World J Urol 18:148-51. 2000
  3. pmc Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:3851-7. 2010
  4. doi request reprint Testicular cancer: when less is more
    Lance C Pagliaro
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 12:271-7. 2010
  5. doi request reprint Multimodality therapy in penile cancer: when and which treatments?
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    World J Urol 27:221-5. 2009
  6. ncbi request reprint Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Urol Oncol 24:487-91. 2006
  7. doi request reprint Systemic therapy for sarcomatoid renal cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 11:913-20. 2011
  8. ncbi request reprint Review of metastatic bladder cancer
    L C Pagliaro
    Department of Genitourinary Medical Oncologyy, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Minerva Urol Nefrol 58:53-71. 2006
  9. ncbi request reprint Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Urol Oncol 21:456-62. 2003
  10. ncbi request reprint A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2988-94. 2003

Detail Information

Publications28

  1. ncbi request reprint Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:2965-70. 2002
    ....
  2. ncbi request reprint Gene therapy for bladder cancer
    L C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    World J Urol 18:148-51. 2000
    ..The results of this study will provide the basis for phase II and phase III trials in which gene therapy will be integrated with existing therapies for improved local control and opportunities for bladder preservation...
  3. pmc Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:3851-7. 2010
    ..We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy...
  4. doi request reprint Testicular cancer: when less is more
    Lance C Pagliaro
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 12:271-7. 2010
    ..This review discusses the decision points with emphasis on the advantages and disadvantages of each management option...
  5. doi request reprint Multimodality therapy in penile cancer: when and which treatments?
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, Unit 1374, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    World J Urol 27:221-5. 2009
    ..To determine the optimal use of multimodality treatment in locally advanced penile cancer, we conducted a literature review...
  6. ncbi request reprint Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Urol Oncol 24:487-91. 2006
    ..We conclude that single-agent capecitabine has minimal activity for the treatment of metastatic RCC...
  7. doi request reprint Systemic therapy for sarcomatoid renal cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Expert Rev Anticancer Ther 11:913-20. 2011
    ..Several ongoing prospective clinical trials are investigating new drug combinations for this disease...
  8. ncbi request reprint Review of metastatic bladder cancer
    L C Pagliaro
    Department of Genitourinary Medical Oncologyy, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Minerva Urol Nefrol 58:53-71. 2006
    ..Recent advances in the fields of tumor genetics, angiogenesis, and tumor immunology have been applied in the ongoing development of novel treatment strategies for this challenging disease...
  9. ncbi request reprint Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Urol Oncol 21:456-62. 2003
    ..These results suggest that forced p53 gene expression is cytotoxic to human bladder cancer cells with either p53 mutant or wild-type background, and that combination with cisplatin is a potential method for overcoming resistance...
  10. ncbi request reprint A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2988-94. 2003
    ..The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma...
  11. ncbi request reprint Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, Box 427, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    J Clin Oncol 21:2247-53. 2003
    ..We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer...
  12. ncbi request reprint Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
    S M Tu
    Department of Genitourinary Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Lancet 357:336-41. 2001
    ..Prostate carcinoma is linked to osteoblastic metastasis. We therefore investigated the value of bone-targeted consolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate...
  13. pmc Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours
    K Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Br J Cancer 86:1555-60. 2002
    ..Because outcomes with this regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in this subset of patients...
  14. doi request reprint Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy
    S L Richey
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA
    Ann Oncol 22:1048-53. 2011
    ..Historically, median overall survival (OS) of patients treated with interferon alpha (IFN-α) without CN was 7.8 months. Median OS in patients treated with targeted therapy (TT) without CN is unknown...
  15. pmc Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
    E Jonasch
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, Texas 77030, USA
    Br J Cancer 98:1336-41. 2008
    ..Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen...
  16. pmc Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment
    Vassiliki Tzelepi
    The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030 3721, USA
    J Clin Oncol 29:2574-81. 2011
    ..We used a preoperative clinical discovery platform to prioritize pathways for assessment as therapeutic targets and to test the hypothesis that the primary site harbors potentially lethal tumors after aggressive treatment...
  17. doi request reprint Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma
    William E Osai
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Anticancer Drugs 19:427-9. 2008
    ..The striking benefit achieved in this heavily treated patient suggests that bevacizumab could have clinically useful antitumor activity in advanced urothelial carcinoma...
  18. ncbi request reprint Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  19. ncbi request reprint Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens
    Peter F Thall
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 99:1613-22. 2007
    ..With the goal of efficiently selecting promising regimens for more advanced trials, we conducted a randomized selection trial of four regimens to identify promising treatments for androgen-independent prostate cancer...
  20. ncbi request reprint Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  21. ncbi request reprint Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma
    Danai D Daliani
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:561-7. 2003
    ....
  22. ncbi request reprint Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carci
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2254-61. 2006
    ..In a randomized Phase II trial, the authors tested the hypothesis that twice-daily low-dose IFN is more effective than daily intermediate-dose IFN in patients with metastatic renal cell cancer (MRCC)...
  23. ncbi request reprint Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Genitourin Cancer 5:144-9. 2006
    ..This is a phase I/II trial of thalidomide with estramustine and paclitaxel in men with androgen-independent prostate cancer (AIPC) who underwent previous chemotherapy...
  24. ncbi request reprint Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Box 427, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:21-6. 2003
    ..8 to 17.1 months), with a 15.9-month median survival for 3 patients with poor performance status and visceral metastases. Further clinical investigation of the biological effect of IL-2 in urothelial carcinoma may be warranted...
  25. ncbi request reprint Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes
    Alan Rodney
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2143-7. 2006
    ..The secondary objective was to evaluate the safety and tolerability of the combination of capecitabine and gemcitabine in these patients...
  26. ncbi request reprint Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7904-10. 2005
    ..We assessed the rate of bone marrow failure in patients with prostate cancer who had received a dose of strontium-89...
  27. ncbi request reprint Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:342-8. 2003
    ..Furthermore, the complicated dosing schedule and toxic effects of the regimen precluded its routine use in the treatment of urothelial carcinoma...
  28. ncbi request reprint Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
    Nizar Tannir
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:497-505. 2006
    ..The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases...